NeuroPace, Inc. NPCE
Updated: 9 Aug 2026
No signal published yet
We already track NeuroPace and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow NeuroPace, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow NeuroPace free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On July 28, 2026, NeuroPace announced that the U.S. FDA requested additional clinical evidence regarding its Premarket Approval Supplement for expanding the RNS System indication to idiopathic generalized epilepsy. The FDA indicated the submission is not approvable in its current form but invited continued dialogue. NeuroPace plans to submit a Submission Issue Request to establish a path toward potential approval.
What Firelda Watch includes for NeuroPace, Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow NeuroPace, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow NeuroPace free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more